Jaguar Health, Inc. paid a special one time dividend of one share of Series R Convertible Preferred Stock, par value $0.0001 per share for each share of…
Jaguar Health, Inc. (JAGX) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on October 15, 2026, Jaguar Health, Inc. (the “Company” or “Jaguar”) paid a special one time dividend of one share of Series R Convertible Preferred Stock, par value $0.0001 per share (the “Series O Preferred Stock”) for each share
- Kind
- special
- Frequency
- one-time
- Record date
- October 13, 2026
- Payable
- October 15, 2026
Facts are quoted from the filing text and checked against it. Details that could not be matched to the text are left out.
How this was made
The 30-second read
Why it matters
The corporate action changes the capital structure, modestly diluting existing shareholders and may affect liquidity and price perception.
Market read
A micro‑cap corporate action with limited market impact, primarily relevant to current shareholders and short‑term traders.
What to watch
Potential tax implications for preferred shareholders and the effect on future financing capacity.
Background
Jaguar Health announced a special dividend of Series R convertible preferred stock, which automatically converted into common stock on November 2, 2026, increasing the total common share count.
Ticker impact
Jaguar Health filed an 8‑K reporting a special one‑time dividend and conversion of Series R preferred into common shares, creating new common shares and potential dilution.
likely slight dilution pressure on the stock
The filing is a primary corporate‑action disclosure; the mechanics are clear and immediate.
Market effects
Minimal impact on the biotech sector; primarily a company‑specific capital‑structure change.
Limited to U.S. micro‑cap investors; no broader regional effect.
Low global relevance; only affects Jaguar Health shareholders.
Counterpoint
Some investors may view the conversion as a catalyst for a short‑term rally if the new shares are seen as a cleanup of preferred equity.
Key entities
- CompanyJaguar Health, Inc.
Biopharmaceutical company filing the 8‑K.
